PT -期刊文章盟艾莎Saand盟方于非盟- Jong李盟Liangge Hsu盟明明宁非盟- Eng罗盟雪莉周TI - CSF炎症和血管活性的介质与贫穷相关功能结果在蛛网膜下腔出血(SAH)患者。(S15.004) DP - 2019年4月09年TA -神经病首页学PG - S15.004 VI - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_Supplement/S15.004.short 4100 - //www.ez-admanager.com/content/92/15_Supplement/S15.004.full所以Neurology2019 4月09年;92 AB -目的:研究协会的CSF炎症和血管活性的功能性结果差的介质在蛛网膜下腔出血(SAH)。背景:最近的证据表明,炎症可能发挥重要作用在血管痉挛和延迟脑缺血的发病机制(DCI) SAH后。我们旨在探索一个面板的细胞因子和血管活性的介质CSF的SAH患者炎症生物标记来确定候选人。设计/方法:脑脊液样本收集通过外部心室排水(EVD)潜在SAH组(N = 67)。我们评估改良Rankin量表(夫人)每隔3个月得分和评估血管痉挛的发生。可怜的功能性结果被定义为夫人在2。血管造影血管痉挛被定义为在任何容器的口径减少50% post-SAH天7脑血管造影。我们比较28的CSF细胞因子(人类磁Luminex化验,R& D系统)post-SAH天1、3和5的结果。连续变量比较学生的t或Wilcoxon等级和测试根据数据分布。Results: In the SAH cohort (mean age 55.1, 69% female), 67% had a Hunts and Hess ≥3 and 89% had a modified Fischer scale of ≥3. 48% had poor 3-month outcome and 36% had poor 6-month outcome. Out of the 28 cytokines, 3 were below measurement range and were excluded from analysis: CCL11/Eotaxin, IL10 and IL5. The top 3 markers showing strongest association with outcome were CSF VEGFR1 (p=0.0014), IL12p70 (p=0.0023) and CCL5/RANTES (p=0.0038).Conclusions: These study results suggest a possible association between elevated VEGFR1 and poor functional outcome following SAH. Further targeted studies are necessary to investigate the role of CSF VEGFR1, IL12p70 and CCL5/RANTES and SAH outcome.Disclosure: Dr. Saand has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Hsu has nothing to disclose. Dr. Ning has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Chou has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Edge Therapeutics, and Merck & Co. Dr. Chou has received royalty, license fees, or contractual rights payments from VL39 9Flagship, and Venture/Massachusetts General Hospital.

map